Atebimetinib (deep cyclic MEK inhibitor) + mGnP links weight preservation to longer OS in 1L pancreatic cancer

Atebimetinib is a MEK inhibitor developed to pair direct anti-tumor activity with mitigation of cancer cachexia/body-mass loss, and was evaluated with modified gemcitabine/nab-paclitaxel (mGnP) in first-line advanced/metastatic pancreatic cancer (reported cohort size 55; AACR abstract A134; Phase 3 ongoing NCT07562152). At an April 24, 2026 data cutoff, 84% of evaluable patients had stable/increased weight at 3 months and showed longer OS than those losing weight (mOS not reached at median follow-up 15.2 months; HR=3.13; log-rank p=0.049); weight stability was also higher than a standard-of-care benchmark dataset (MWU p<0.001; Cliff’s δ=+0.48). Tumor shrinkage appeared “threshold-dependent” rather than depth-dependent: OS with SLD≤−30% was similar to SLD 0% to −30%, while SLD>0% tracked with worse OS; among patients with low baseline FAACT-ACS (≤37), 66% achieved ≥4-point ACS improvement on treatment across RECIST responses—suggesting symptom/weight benefits may not strictly require deep radiographic responses. For real-world SOC anchors, first-line gemcitabine/nab-paclitaxel historically delivers mOS ~8.5 months, and FOLFIRINOX ~11.1 months in fit patients—so the previously reported 17.3-month mOS signal for atebimetinib+mGnP (from the linked ASCO abstract) would be above typical chemotherapy-only expectations, but cross-trial comparisons are fragile without randomized data.